The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: A comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A)

Journal of Clinical Pathology

Volumn 54, Issue 3, 2001, Pages 196-200

  Clarkson, K S ^a   Sturdgess, I C ^a   Molyneux, A J ^a  

^a NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

A103 (anti melan A); Immunohistochemistry; Melanocytic lesions; T311 (anti tyrosinase

Indexed keywords

A 103; ENZYME ANTIBODY; FORMALDEHYDE; MELAN A; MONOCLONAL ANTIBODY A103; MONOCLONAL ANTIBODY HMB 45; MONOCLONAL ANTIBODY T311; MONOPHENOL MONOOXYGENASE; PARAFFIN; PROTEIN ANTIBODY; PROTEIN S 100; T 311; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; PRIORITY JOURNAL; RELIABILITY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; ENZYME TESTS; HUMANS; MELANOMA; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; NEVUS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035089775     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.54.3.196     Document Type: Article

References (26)

1. Immunohistochemical study on the distribution of alpha and beta subunits of S100 protein in human neoplasms and normal tissues
2. New site of human S100 immunoreactivity detected with monoclonal antibodies
3. HMB45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation
4. Monoclonal antibodies specific for melanocytic tumours distinguish subpopulations of melanocytes
5. HMB-45 recognises stimulated melanocytes
6. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB45 in malignant melanoma and melanoma variants
7. A103 - An anti-melan-A monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues
8. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma
9. Pigmentation genes: The tyrosinase gene family and the pmel 17 gene family
10. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma
11. Detection of tyrosinase mRNA from the blood of melanoma patients
12. Molecular staging of malignant melanoma: Correlation with clinical outcome
13. Lymph node micrometastases of cutaneous melanoma: Increased sensitivity of molecular diagnosis in comparison to immunohistochemistry
14. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections
15. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: Frequency and distribution
16. Diagnosing melanoma
17. HMB45. A review
18. Desmoplastie and spindle-cell malignant melanoma. An immunohistochemical study
19. Special stains in the evaluation of melanocytic lesions
20. Immunohistochemistry in the evaluation of melanocytic tumours
21. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI beteb, HMB-50 and HMB-45 are encoded by a single cDNA
22. Molecular characterization of the melanocytic lineage-specific antigen gp 100
23. Nevus cell maturation or atrophy?
24. Breast carcinoma positive for the melanoma marker (HMB45). HMB45 immunoreactivity in normal and neoplastic breast
25. Reactivity of HMB45 monoclonal antibody with sweat gland tumours of the skin
26. Immunoreactivity for A103, an antibody to melan-A (MART1) in adrenocortical and other steroid tumours